vs
Side-by-side financial comparison of NextPlat Corp (NXPL) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.
NextPlat Corp is the larger business by last-quarter revenue ($12.8M vs $7.0M, roughly 1.8× Relay Therapeutics, Inc.). NextPlat Corp produced more free cash flow last quarter ($-339.0K vs $-235.9M).
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
NXPL vs RLAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.8M | $7.0M |
| Net Profit | $-5.1M | — |
| Gross Margin | 14.3% | — |
| Operating Margin | -28.9% | — |
| Net Margin | -40.2% | — |
| Revenue YoY | -21.1% | — |
| Net Profit YoY | -70.6% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.8M | $7.0M | ||
| Q3 25 | $13.8M | $0 | ||
| Q2 25 | $13.2M | — | ||
| Q1 25 | $14.5M | $7.7M | ||
| Q4 24 | $16.2M | $0 | ||
| Q3 24 | $15.4M | $0 | ||
| Q2 24 | $17.0M | $0 | ||
| Q1 24 | $17.5M | $10.0M |
| Q4 25 | $-5.1M | — | ||
| Q3 25 | $-2.2M | $-74.1M | ||
| Q2 25 | $-1.8M | — | ||
| Q1 25 | $-1.3M | $-77.1M | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | $-4.2M | $-88.1M | ||
| Q2 24 | $-5.3M | $-92.2M | ||
| Q1 24 | $-1.5M | $-81.4M |
| Q4 25 | 14.3% | — | ||
| Q3 25 | 19.9% | — | ||
| Q2 25 | 21.8% | — | ||
| Q1 25 | 23.8% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 23.2% | — | ||
| Q2 24 | 34.5% | — | ||
| Q1 24 | 27.8% | — |
| Q4 25 | -28.9% | — | ||
| Q3 25 | -14.5% | — | ||
| Q2 25 | -13.8% | — | ||
| Q1 25 | -10.2% | -1105.2% | ||
| Q4 24 | -14.1% | — | ||
| Q3 24 | -52.1% | — | ||
| Q2 24 | -64.1% | — | ||
| Q1 24 | -10.5% | -903.0% |
| Q4 25 | -40.2% | — | ||
| Q3 25 | -15.9% | — | ||
| Q2 25 | -13.5% | — | ||
| Q1 25 | -9.2% | -1003.6% | ||
| Q4 24 | -18.6% | — | ||
| Q3 24 | -27.4% | — | ||
| Q2 24 | -31.3% | — | ||
| Q1 24 | -8.5% | -813.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.43 | ||
| Q2 25 | — | — | ||
| Q1 25 | $-0.05 | $-0.46 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-0.22 | $-0.63 | ||
| Q2 24 | — | $-0.69 | ||
| Q1 24 | $-0.08 | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.7M | $84.0M |
| Total DebtLower is stronger | $1.3M | — |
| Stockholders' EquityBook value | $17.3M | $567.1M |
| Total Assets | $27.5M | $621.3M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.7M | $84.0M | ||
| Q3 25 | $13.9M | $91.6M | ||
| Q2 25 | $16.6M | — | ||
| Q1 25 | $17.7M | $93.5M | ||
| Q4 24 | $20.0M | $124.3M | ||
| Q3 24 | $20.4M | $152.4M | ||
| Q2 24 | $24.9M | $134.1M | ||
| Q1 24 | $23.5M | $152.9M |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $17.3M | $567.1M | ||
| Q3 25 | $21.4M | $607.7M | ||
| Q2 25 | $23.5M | — | ||
| Q1 25 | $25.3M | $721.1M | ||
| Q4 24 | $27.3M | $777.8M | ||
| Q3 24 | $22.5M | $838.9M | ||
| Q2 24 | $26.5M | $681.7M | ||
| Q1 24 | $31.2M | $745.8M |
| Q4 25 | $27.5M | $621.3M | ||
| Q3 25 | $30.0M | $670.0M | ||
| Q2 25 | $31.0M | — | ||
| Q1 25 | $35.2M | $799.4M | ||
| Q4 24 | $37.1M | $871.3M | ||
| Q3 24 | $41.1M | $930.1M | ||
| Q2 24 | $51.5M | $772.5M | ||
| Q1 24 | $65.1M | $841.4M |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.05× | — | ||
| Q1 24 | 0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-302.0K | $-235.5M |
| Free Cash FlowOCF − Capex | $-339.0K | $-235.9M |
| FCF MarginFCF / Revenue | -2.6% | -3370.0% |
| Capex IntensityCapex / Revenue | 0.3% | 5.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-622.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-302.0K | $-235.5M | ||
| Q3 25 | $-2.7M | $-62.1M | ||
| Q2 25 | $-1.0M | — | ||
| Q1 25 | $-2.1M | $-73.2M | ||
| Q4 24 | $-476.0K | $-249.1M | ||
| Q3 24 | $-4.6M | $-75.1M | ||
| Q2 24 | $2.3M | $-65.8M | ||
| Q1 24 | $-2.7M | $-50.3M |
| Q4 25 | $-339.0K | $-235.9M | ||
| Q3 25 | — | $-62.1M | ||
| Q2 25 | $-1.1M | — | ||
| Q1 25 | $-2.1M | $-73.6M | ||
| Q4 24 | $-508.0K | $-251.1M | ||
| Q3 24 | $-4.7M | $-75.3M | ||
| Q2 24 | $2.2M | $-65.8M | ||
| Q1 24 | $-2.7M | $-52.1M |
| Q4 25 | -2.6% | -3370.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | -8.0% | — | ||
| Q1 25 | -14.3% | -958.4% | ||
| Q4 24 | -3.1% | — | ||
| Q3 24 | -30.6% | — | ||
| Q2 24 | 13.2% | — | ||
| Q1 24 | -15.7% | -520.7% |
| Q4 25 | 0.3% | 5.9% | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | 5.0% | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.4% | 17.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
RLAY
Segment breakdown not available.
